Humacyte’s (HUMA) “Buy” Rating Reiterated at Benchmark

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reissued by research analysts at Benchmark in a note issued to investors on Thursday,Benzinga reports.

HUMA has been the subject of a number of other research reports. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target (up previously from $12.00) on shares of Humacyte in a report on Friday, December 20th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $13.71.

Humacyte Stock Up 9.8 %

Shares of NASDAQ:HUMA traded up $0.34 during trading on Thursday, hitting $3.77. 852,719 shares of the stock traded hands, compared to its average volume of 2,218,799. The company has a fifty day moving average price of $4.38 and a two-hundred day moving average price of $4.99. Humacyte has a 52-week low of $2.81 and a 52-week high of $9.97. The company has a market cap of $473.86 million, a price-to-earnings ratio of -2.78 and a beta of 1.30.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of HUMA. Vontobel Holding Ltd. purchased a new stake in Humacyte during the 4th quarter worth approximately $50,000. Petros Family Wealth LLC purchased a new stake in shares of Humacyte during the fourth quarter worth approximately $50,000. Syon Capital LLC acquired a new position in Humacyte in the 4th quarter valued at $54,000. Brookstone Capital Management acquired a new position in Humacyte in the 4th quarter valued at $56,000. Finally, ACT Wealth Management LLC purchased a new position in Humacyte in the 4th quarter valued at $57,000. 44.71% of the stock is owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.